Plante TB, et al. - In the Systolic Blood Pressure Intervention Trial (SPRINT), researchers evaluated differences in incident atherosclerotic cardiovascular disease (ASCVD) and serious adverse event (SAE) with intensive blood pressure (BP) control across the spectrum of 10-year ASCVD risk. A total of 9,361 participants ≥ 50 years old and ≥ 1 CVD risk factor were randomized to standard or intensive BP control (< 120 or 130-139 mm Hg). Excluded subjects were adults with clinical ASCVD or age ≥ 80. Among all and across quartiles of baseline risk, hazard ratios and risk differences of incident ASCVD events or SAEs were compared. Findings demonstrated that initiation of antihypertensives may be beneficial for lower risk adults with stage 1 hypertension meeting SPRINT eligibility.